FPI-2265

Phase 2Small molecule

FFusion Pharmaceuticals Inc.

FPI-2265 is one of 87 small molecule programs targeting Prostate Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerRecruiting

Metastatic Prostate CancerRecruiting

Metastatic Castration-Resistant Prostate CancerActive, not recruiting

Prostate CancerPhase 2

Recruiting

Metastatic Prostate CancerPreclinical

Recruiting

Metastatic Castration-Resistant Prostate CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

348 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Phase 3

20 2

Cabometyx

Bristol-Myers Squibb

Phase 3

12 3

Zejula

GGlaxo Dba Glaxosmithkline

Phase 3

10 4

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

7 5

Antibiotic

Pfizer

Phase 3

1 6

Lutetium Lu-177 PNT2002

JJonsson Comprehensive Cancer Center

Phase 3

4 7

Rhpsma-7.3 (18f)

BBlue Earth Diagnostics

Phase 3

4 8

HC-1119

HHinova Pharmaceuticals Inc.

Phase 3

2 9

FPI-2265

FFusion Pharmaceuticals Inc.

Phase 2

2 10

Trexall

Jazz Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Metastatic Castration-Resistant Prostate Cancer

NCT06909825

Q3 2029

PreclinicalRecruiting

Metastatic Prostate Cancer

NCT07590934

Q1 2031

Phase 2Recruiting

Prostate Cancer

NCT06402331

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Recruiting·FFusion Pharmaceuticals Inc.·Phase 2·NCT06402331·100 enrolled

Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).

Active, not recruiting·FFusion Pharmaceuticals Inc.·Phase 2·NCT05219500·115 enrolled

Metastatic Castration-Resistant Prostate Cancer1 trial

A Phase 2, Open-label, Multi-centre Study of FPI-2265 (225Ac-PSMA-I&T) and Olaparib in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Active, not recruiting·FFusion Pharmaceuticals Inc.·Phase 2·NCT06909825·85 enrolled

Metastatic Prostate Cancer1 trial

A Phase Ib/II, Open-label, Multi-centre, Platform Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Multiple Anti-Cancer Agents in Metastatic Prostate Cancer

Recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT07590934·152 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for FPI-2265. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FPI-2265 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FPI-2265. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fusion Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: FFusion Pharmaceuticals Inc.

FPI-2265

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2029

Q1 2031

Trials by Indication[1]

Prostate Cancer2 trials

Metastatic Castration-Resistant Prostate Cancer1 trial

Metastatic Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News